FDA approves Ocrevus to treat Primary Progressive MS

On March 28, the U.S. Food and Drug Administration approved Ocrevus (ocrelizumab) to treat adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS). This is the first drug approved by the FDA for PPMS. Ocrevus is an intravenous infusion given by a health care professional. "Multiple sclerosis can have ["]

The post FDA approves Ocrevus to treat Primary Progressive MS appeared first on Outbreak News Today.